Navigation Links
InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
Date:10/23/2007

SACRAMENTO, Calif., Oct. 23 /PRNewswire/ -- InVitria has released data that shows that Lacromin, a recombinant growth factor for cell culture media outperforms transferrin and provides a cost-effective solution to rising transferrin costs. Because Lacromin is produced in a completely animal-free system, it provides improved productivity and safety over animal-derived alternatives including bovine and human transferrin. In addition data has shown that Lacromin significantly increased the productivity of antibody production when compared with these other sources of transferrin.

"We are excited about Lacromin and its success as safer, more productive replacement for transferrin," said Victor Hicks, Vice President and Commercial Director, InVitria. "Lacromin(TM) provides a cost-effective solution to the challenge of rising transferrin costs and increasing concern over the use of animal-derived ingredients in cell culture. Given the FDA's preference for non-animal derived cell culture media ingredients, animal-free recombinant proteins like Lacromin(TM) are a real breakthrough for this market."

InVitria markets Lacromin(TM) to customers that seek a serum-free and animal component free cell culture media source for their biopharmaceutical production.

About Lacromin(TM)

Lacromin(TM) is recombinant human lactoferrin derived from plants. Lacromin(TM) holds many advantages over current cell culture media ingredients:

-- Strong growth factor

Lacromin(TM) has been shown to promote cell growth in many cell lines,

including Chinese Hamster Ovary (CHO) cells and Mouse Hybridoma cells.

-- Outperforms Transferrin

Lacromin(TM) promotes higher cell density and reduces cell doubling

time when compared with Transferrin.

-- Replaces Animal Derived Transferrin

Since Lacromin(TM) is derived from plants, it is free of any viral or

prion contaminant risks.

-- Improves IgG Productivity

In Hybridoma cells, Lacromin(TM) increased IgG productivity by 50%

versus Transferrin and by 6% versus Fetal Bovine Serum (FBS).

About InVitria

InVitria is a global supplier of animal-free products for use in bioprocessing, excipients, research and diagnostics.

InVitria's mission is to develop and supply our customers with products that deliver faster time to market, enhanced productivity, and improved safety.

For more information about InVitria, see our website at http://www.InVitria.com

Or Contact:

info@InVitria.com

1-800-916-8311

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.


'/>"/>
SOURCE InVitria
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Transgenic Animals
3. Bifidobacterium animalis
4. Bifidobacterium animalis
5. The QIAGEN Guide to Animal Cell Culture
6. The QIAGEN Guide to Animal Cell Culture
7. The QIAGEN Guide to Animal Cell Culture
8. The QIAGEN Guide to Animal Cell Culture
9. The QIAGEN Guide to Animal Cell Culture
10. The QIAGEN Guide to Animal Cell Culture
11. An Animal-Free DNase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):